Nevertheless, the combination blockade of IDO1 and PD‐1/PD‐L1 might be more appropriate for inflamed tumors, given that the driving factor for IDO1 expression in NSCLC patients is likely inflammation rather than the tumor itself.108. The gene discussed is IDO1; the disease is non-small cell lung carcinoma.